Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Etanercept in methotrexate-resistant JIA-related uveitis.

Saeed MU, Raza SH, Goyal S, Cleary G, Newman WD, Chandna A.

Semin Ophthalmol. 2014 Jan;29(1):1-3. doi: 10.3109/08820538.2013.839802. Epub 2013 Oct 31.

PMID:
24175644
2.

Etanercept therapy in children with treatment-resistant uveitis.

Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T.

Arthritis Rheum. 2001 Jun;44(6):1411-5.

3.

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.

Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K.

Ann Rheum Dis. 2007 Apr;66(4):548-50. Epub 2006 Oct 26.

4.

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group.

Ann Rheum Dis. 2009 Apr;68(4):519-25. doi: 10.1136/ard.2007.087593. Epub 2008 Apr 15.

PMID:
18413440
5.

Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.

Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Higuchi R, Kawano Y, Yokota S, Sugiyama N, Yuasa H, Fletcher T, Wajdula JS.

Mod Rheumatol. 2012 Sep;22(5):720-6. doi: 10.1007/s10165-011-0578-5. Epub 2012 Jan 4.

PMID:
22212889
6.

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.

Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2009 Sep;60(9):2794-804. doi: 10.1002/art.24777.

7.

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.

Arthritis Rheum. 2003 Apr;48(4):1093-101.

8.
9.

Etanercept and uveitis in patients with juvenile idiopathic arthritis.

Schmeling H, Horneff G.

Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26.

PMID:
15855187
10.

A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.

Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS.

Arthritis Rheum. 2005 Feb 15;53(1):18-23.

11.

Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.

Windschall D, Müller T, Becker I, Horneff G.

Clin Rheumatol. 2015 Jan;34(1):61-9. doi: 10.1007/s10067-014-2744-6. Epub 2014 Jul 18.

PMID:
25034081
12.

Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.

Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, Hull RG, Venning HE, Rahman JK, Cummins CL; British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register.

Rheumatology (Oxford). 2011 Jan;50(1):189-95. doi: 10.1093/rheumatology/keq308. Epub 2010 Nov 3.

PMID:
21047801
13.

Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.

Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.

JAMA. 2011 Dec 7;306(21):2340-7. doi: 10.1001/jama.2011.1671. Epub 2011 Nov 6.

PMID:
22056397
14.

Response of pediatric uveitis to tumor necrosis factor-α inhibitors.

Lerman MA, Burnham JM, Chang PY, Daniel E, Foster CS, Hennessy S, Jabs DA, Joffe MM, Kaçmaz RO, Levy-Clarke GA, Mills MD, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Kempen JH.

J Rheumatol. 2013 Aug;40(8):1394-403. doi: 10.3899/jrheum.121180. Epub 2013 Jul 1.

15.

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.

Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2009 May;68(5):635-41. doi: 10.1136/ard.2007.087411. Epub 2008 Apr 15.

PMID:
18413443
16.

Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.

van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM.

J Rheumatol. 2011 Jul;38(7):1441-6. doi: 10.3899/jrheum.100809. Epub 2011 Apr 1.

PMID:
21459936
17.

Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.

Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.

J Rheumatol. 2007 May;34(5):1146-50. Epub 2007 Mar 1.

PMID:
17343318
18.

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ.

N Engl J Med. 1999 Jan 28;340(4):253-9.

19.

Clinical remission in juvenile idiopathic arthritis after termination of etanercept.

Postępski J, Kobusińska K, Olesińska E, Osińska V, Opoka-Winiarska V.

Rheumatol Int. 2013 Oct;33(10):2657-60. doi: 10.1007/s00296-012-2468-3. Epub 2012 Jul 21.

20.

Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.

Aikawa NE, França IL, Ribeiro AC, Sallum AM, Bonfa E, Silva CA.

Vaccine. 2015 Jan 29;33(5):604-9. doi: 10.1016/j.vaccine.2014.12.030. Epub 2014 Dec 29.

PMID:
25554240

Supplemental Content

Support Center